Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance
This research was partly funded by grants from SFA. In “Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance,” the researchers used several cutting-edge techniques to demonstrate that the aggressive alveolar RMS subtype contains two cell subtypes that drive tumor growth. While chemotherapy eliminates one of these cell subtypes, it enriches the other. They then looked for drugs that may lead to better treatment options and identified a combination of two inhibitors that targets a critical cell pathway. This combination appears to inhibit tumor growth in cell culture indicating that the pathway they act on is a promising therapeutic target.